Monoclonal Antibody Therapies for High Risk Neuroblastoma
Wayne L Furman Department of Oncology, St. Jude Children’s Research Hospital, Memphis, TN, USACorrespondence: Wayne L FurmanDepartment of Oncology, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USATel +1-901-595-2403Fax +1– 901-521-9...
Guardado en:
Autor principal: | Furman WL |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4d92fc6f80074bf6bbc35d6506e3485d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy
por: Keyel ME, et al.
Publicado: (2018) -
A Novel pH-Sensitive Multifunctional DNA Nanomedicine: An Enhanced and Harmless GD2 Aptamer-Mediated Strategy for Guiding Neuroblastoma Antitumor Therapy
por: Zhang L, et al.
Publicado: (2021) -
Nanomicellar Lenalidomide–Fenretinide Combination Suppresses Tumor Growth in an MYCN Amplified Neuroblastoma Tumor
por: Orienti I, et al.
Publicado: (2020) -
Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes
por: Ramona Erber, et al.
Publicado: (2021) -
How Can We Engineer CAR T Cells to Overcome Resistance?
por: Glover M, et al.
Publicado: (2021)